synaptonemal complex central element protein 1Genealiases: C10orf94 · CT76 · POF12 · SPGF15
Q-omics provides the consensus-scored SYCE1 profile across patient tissues and cancer cell-line models. SYCE1 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SYCE1 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SYCE1 RNA expression shows 11,029 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, THCA, and THYM as cancer lineages where SYCE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYCE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYCE1 survival associations across molecular data types. SYCE1 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYCE1 RNA expression–survival associations across cancer types. High SYCE1 expression shows unfavorable associations in COAD, LUAD and UVM, but favorable associations in LGG, LAML and SARC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .011). Together, the overview and detailed table identify COAD as the clearest survival context for SYCE1 RNA expression.
This table summarizes SYCE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SYCE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYCE1 shows lower tumor expression in THCA, BRCA, KICH, STAD, KIRC and KIRP. The THCA box plot shows higher SYCE1 RNA expression in normal versus tumor tissue (log2 FC = −0.528, t-test p < 0.001).
This table shows molecular features associated with SYCE1 in patient tissues and cancer cell lines. In patient samples, SYCE1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SYCE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
